ArticleJournal of immunology research2026
Distinct Longitudinal Trajectories of SLEDAI-2K Scores Predict Prognosis in Systemic Lupus Erythematosus Based on Group-Based Trajectory Modeling.
Article in Journal of immunology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Assessing the Relationship Between Multidimensional Area-Level Indicators and Lupus Disease Activity in Children.Children (Basel, Switzerland) · 2026Article
- Distinct Longitudinal Trajectories of SLEDAI-2K Scores Predict Prognosis in Systemic Lupus Erythematosus Based on Group-Based Trajectory Modeling.Journal of immunology research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTo apply group-based trajectory modeling (GBTM) to longitudinal real world data from patients with systemic lupus erythematosus (SLE) to identify distinct disease activity trajectories and factors associated with 6 month clinical status.
methodsA total of 91 patients with SLE treated between 2017 and 2024 were included. SLE Disease Activity Index 2000 (SLEDAI-2K) scores were assessed at baseline, 3 months, and 6 months. GBTM was used to characterize longitudinal disease activity patterns. Heatmap clustering analysis was performed to compare clinical laboratory variables and SLEDAI-2K scores across trajectory groups and to further explore their association with 6 month clinical status.
resultsTwo distinct disease activity trajectories were identified. Class 1, comprising patients with higher initial SLEDAI-2K scores, was predominantly composed of nonremission cases (90.91%). Class 2, characterized by lower initial SLEDAI-2K scores, showed a more balanced distribution of nonremission (46.81%) and remission (53.19%) patients. At 6 months, the remission subgroup had significantly lower SLEDAI-2K scores and lower urinary biomarker levels, including 24 h urinary microalbumin (24 h-UMA), 24 h urinary micrototal protein (24 h-UMTP), UMA, and UMTP, than the nonremission subgroup.
conclusionsLongitudinal monitoring of SLEDAI-2K trajectories may help identify patients at risk for persistent high disease activity or nonremission at 6 months and those who may benefit from closer monitoring and treatment adjustment. These findings support a stratified management approach in SLE based on trajectory profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.